Parvoduk

RSS

Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus
MedicineVeterinaryLapsed

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (279.17 KB - PDF)

Zobacz

español (ES) (388.86 KB - PDF)

Zobacz

čeština (CS) (432.85 KB - PDF)

Zobacz

dansk (DA) (386.36 KB - PDF)

Zobacz

Deutsch (DE) (392.74 KB - PDF)

Zobacz

eesti (ET) (372.5 KB - PDF)

Zobacz

ελληνικά (EL) (456.39 KB - PDF)

Zobacz

français (FR) (390.28 KB - PDF)

Zobacz

hrvatski (HR) (547.54 KB - PDF)

Zobacz

italiano (IT) (391.31 KB - PDF)

Zobacz

latviešu (LV) (456.12 KB - PDF)

Zobacz

lietuvių (LT) (421.48 KB - PDF)

Zobacz

magyar (HU) (449.76 KB - PDF)

Zobacz

Malti (MT) (440.69 KB - PDF)

Zobacz

Nederlands (NL) (388.36 KB - PDF)

Zobacz

polski (PL) (432.82 KB - PDF)

Zobacz

português (PT) (389.06 KB - PDF)

Zobacz

română (RO) (418.94 KB - PDF)

Zobacz

slovenčina (SK) (436.71 KB - PDF)

Zobacz

slovenščina (SL) (428.53 KB - PDF)

Zobacz

suomi (FI) (387.48 KB - PDF)

Zobacz

svenska (SV) (386.11 KB - PDF)

Zobacz

Product information

български (BG) (1.19 MB - PDF)

Zobacz

español (ES) (804.6 KB - PDF)

Zobacz

čeština (CS) (1.03 MB - PDF)

Zobacz

dansk (DA) (817.13 KB - PDF)

Zobacz

Deutsch (DE) (901.86 KB - PDF)

Zobacz

eesti (ET) (803.72 KB - PDF)

Zobacz

ελληνικά (EL) (1.2 MB - PDF)

Zobacz

français (FR) (816.73 KB - PDF)

Zobacz

hrvatski (HR) (1.23 MB - PDF)

Zobacz

italiano (IT) (816.1 KB - PDF)

Zobacz

latviešu (LV) (1.05 MB - PDF)

Zobacz

lietuvių (LT) (953.35 KB - PDF)

Zobacz

magyar (HU) (997.58 KB - PDF)

Zobacz

Malti (MT) (1.06 MB - PDF)

Zobacz

Nederlands (NL) (808.14 KB - PDF)

Zobacz

polski (PL) (1.17 MB - PDF)

Zobacz

português (PT) (803.42 KB - PDF)

Zobacz

română (RO) (936.44 KB - PDF)

Zobacz

slovenčina (SK) (1.06 MB - PDF)

Zobacz

slovenščina (SL) (1.06 MB - PDF)

Zobacz

suomi (FI) (791.59 KB - PDF)

Zobacz

svenska (SV) (796.96 KB - PDF)

Zobacz

Íslenska (IS) (803.26 KB - PDF)

Zobacz

norsk (NO) (815.13 KB - PDF)

Zobacz
Latest procedure affecting product information:R/0006
09/01/2019

български (BG) (189.97 KB - PDF)

Zobacz

español (ES) (281.53 KB - PDF)

Zobacz

čeština (CS) (304.72 KB - PDF)

Zobacz

dansk (DA) (298.36 KB - PDF)

Zobacz

Deutsch (DE) (302.28 KB - PDF)

Zobacz

eesti (ET) (285.5 KB - PDF)

Zobacz

ελληνικά (EL) (325.92 KB - PDF)

Zobacz

français (FR) (335.93 KB - PDF)

Zobacz

hrvatski (HR) (307.68 KB - PDF)

Zobacz

italiano (IT) (299.37 KB - PDF)

Zobacz

latviešu (LV) (340.5 KB - PDF)

Zobacz

lietuvių (LT) (297.31 KB - PDF)

Zobacz

magyar (HU) (303.78 KB - PDF)

Zobacz

Malti (MT) (306.38 KB - PDF)

Zobacz

Nederlands (NL) (313.36 KB - PDF)

Zobacz

polski (PL) (299.63 KB - PDF)

Zobacz

português (PT) (297.7 KB - PDF)

Zobacz

română (RO) (312.51 KB - PDF)

Zobacz

slovenčina (SK) (304.5 KB - PDF)

Zobacz

slovenščina (SL) (297.92 KB - PDF)

Zobacz

suomi (FI) (295.81 KB - PDF)

Zobacz

svenska (SV) (293.03 KB - PDF)

Zobacz

Íslenska (IS) (292.58 KB - PDF)

Zobacz

norsk (NO) (298.06 KB - PDF)

Zobacz

Product details

Name of medicine
Parvoduk
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01BD03

Pharmacotherapeutic group

  • duck parvovirus
  • Live viral vaccines
  • Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Authorisation details

EMA product number
EMEA/V/C/002740
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
11/04/2014
Lapse of marketing authorisation
01/04/2019
Revision
2

Assessment history

This page was last updated on

Share this page